Literature DB >> 7843719

31P magnetic resonance spectroscopy of the liver: correlation with standardized serum, clinical, and histological changes in diffuse liver disease.

H N van Wassenaer-van Hall1, J van der Grond, J van Hattum, C Kooijman, T U Hoogenraad, W P Mali.   

Abstract

The goal of this study was to analyze the possibilities of 31P MR spectroscopy to detect abnormal hepatic histological changes in patients with diffuse liver disease. 31P MR spectroscopy was performed, on a 1.5 T whole-body spectrometer using an image guided localization technique (ISIS), on 38 patients with various diffuse liver diseases, who all underwent histological and serum analysis, and 22 healthy volunteers. Phosphomonoester expressed as a fraction of total phosphorus (PME/P) showed a correlation with abnormal serum aspartate transaminase (AST), histological intralobular degeneration/focal necrosis, portal inflammation, and piecemeal necrosis. We found a lower correlation for PME/P with fibrosis. It was not possible to differentiate between fibrosis and cirrhosis. In summary, 31P MR spectroscopy is a technique to detect intralobular degeneration, inflammation and necrosis and to a less extent fibrosis. No diagnostic value was found with respect to steatosis and cholangitis. Furthermore, 31P MR spectroscopy is a poor method for classifying patients into diagnostic categories.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7843719

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  8 in total

Review 1.  Magnetic resonance spectroscopy to study hepatic metabolism in diffuse liver diseases, diabetes and cancer.

Authors:  Pieter C Dagnelie; Susanne Leij-Halfwerk
Journal:  World J Gastroenterol       Date:  2010-04-07       Impact factor: 5.742

2.  A comparison of MR elastography and 31P MR spectroscopy with histological staging of liver fibrosis.

Authors:  Edmund M Godfrey; Andrew J Patterson; Andrew N Priest; Susan E Davies; Ilse Joubert; Anant S Krishnan; Nyree Griffin; Ashley S Shaw; Graeme J Alexander; Michael E Allison; William J H Griffiths; Alexander E S Gimson; David J Lomas
Journal:  Eur Radiol       Date:  2012-07-01       Impact factor: 5.315

3.  Absolute quantification of human liver metabolite concentrations by localized in vivo 31P NMR spectroscopy in diffuse liver disease.

Authors:  Bengt Norén; Peter Lundberg; Marcus Ressner; Staffan Wirell; Sven Almer; Orjan Smedby
Journal:  Eur Radiol       Date:  2004-09-03       Impact factor: 5.315

4.  Parametric exploration of the liver by magnetic resonance methods.

Authors:  Paul E Sijens
Journal:  Eur Radiol       Date:  2009-06-06       Impact factor: 5.315

Review 5.  In-vivo31P-MRS of skeletal muscle and liver: A way for non-invasive assessment of their metabolism.

Authors:  Ladislav Valkovič; Marek Chmelík; Martin Krššák
Journal:  Anal Biochem       Date:  2017-01-21       Impact factor: 3.365

6.  Ultra-high-field magnetic resonance spectroscopy in non-alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non-alcoholic steatohepatitis and advanced fibrosis.

Authors:  Stefan Traussnigg; Christian Kienbacher; Martin Gajdošík; Ladislav Valkovič; Emina Halilbasic; Judith Stift; Christian Rechling; Harald Hofer; Petra Steindl-Munda; Peter Ferenci; Fritz Wrba; Siegfried Trattnig; Martin Krššák; Michael Trauner
Journal:  Liver Int       Date:  2017-05-20       Impact factor: 5.828

7.  Phosphodiester content measured in human liver by in vivo 31 P MR spectroscopy at 7 tesla.

Authors:  Lucian A B Purvis; William T Clarke; Ladislav Valkovič; Christina Levick; Michael Pavlides; Eleanor Barnes; Jeremy F Cobbold; Matthew D Robson; Christopher T Rodgers
Journal:  Magn Reson Med       Date:  2017-02-28       Impact factor: 4.668

8.  Comparing localized and nonlocalized dynamic 31P magnetic resonance spectroscopy in exercising muscle at 7 T.

Authors:  Martin Meyerspeer; Simon Robinson; Christine I Nabuurs; Tom Scheenen; Adrian Schoisengeier; Ewald Unger; Graham J Kemp; Ewald Moser
Journal:  Magn Reson Med       Date:  2012-02-14       Impact factor: 4.668

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.